Neuroprotective properties of arginine: conclusiveness 2016


neuroprotective, stroke, treatment, arginine, Valargin.

How to Cite

Svyrydova, N. (2016). Neuroprotective properties of arginine: conclusiveness 2016. East European Journal of Neurology, (4(10), 70-77.


Systemic or oral administration of arginine improves the function of cardiovascular system and reduces myocardial ischemia in patients with coronary heart disease, lowers blood pressure in hypertensive patients and in patients with normal or poor kidney function. Although the concentration of arginine in the plasma do not vary with hypercholesterolemia, oral or intravenous administration of arginine can significantly reduce endothelial dysfunction in patients with hypercholesterolemia and in smokers. The main action Arginina due to its role as a precursor of nitric oxide synthesis. L-arginine affects the pathophysiological mechanisms that exist method, the progression of atherosclerosis. L-arginine can be considered as an integrative part of a multimodal approach to combating acute cerebrovascular pathology, development-it excitotoxicity and ischemic brain injury. Neuroprotective properties of the L-arginine suggests that they may have potential as neuroprotective therapy in stroke patients.


Affandi M.M., Minaketan Tripathy, Majeed A.B. Conductometric and volumetric studies of atorvastatin in aqueous solution of ar-ginine// J. Adv. Pharm. Technol. Res. – 2016.- Jul-Sep; 7(3): 80–86.

Williams H.D., Trevaskis N.L., Charman S.A., Shanker al. Strategies to address low drug solubility in discovery and development//Pharmacol Rev. -2013;65:315–499.

Di L., Fish P.V., Mano T. Bridging solubility between drug discovery and development//Drug Discov Today.- 2012;17:486–95.

Lau Y.Y., Okochi H., Huang Y., Benet L.Z. Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: Relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism// Drug Metab Dis-pos. -2006;34:1175–81.

Uddin R., Ali F., Biswas S.K. Water solubility enhancement of Atorvastatin by solid dispersion method//Stamford J Pharm Sci.- 2010;3:43–6.

Shayanfar A., Ghavimi H., Hamishekar H., Jouyban A. Coamorphous atorvastatin calcium to improve its physicochemical and pharmacokinetic properties// J Pharm Pharm Sci. -2013;16:577–87.

Choudharya A., Ranaa A.C., Aggarwalb G., Kumara V., Zakir F. Development and characteriza-tion of an atorvastatin solid dispersion formulation using skimmed milk for improved oral bioavailabil-ity// Acta Pharm Sin B.- 2012;2:421–8.

Anwar M., Warsi M.H., Mallick N., Akhter S., Gahoi S., Jain G.K., et al. Enhanced bioavailability of nano-sized chitosan-atorvastatin conjugate after oral administration to rats// Eur J Pharm Sci.- 2011;44:241–9

Shen H., Zhong M. Preparation and evaluation of self-microemulsifying drug delivery systems (SMEDDS) containing atorvastatin// J Pharm Pharmacol.- 2006;58:1183–91.

Tapiero H., Mathé G., Couvreur P., Tew K.D. L-arginine //Biomed Pharmacother. 2002;56:439–45

Higashi Y., Oshima T., Ozono R., Matsuura H., Kambe M., Kajiyama G. Effect of L-arginine infusion on systemic and renal hemodynamics in hypertensive patients// Am J Hypertens. -1999;12(1 Pt 1):8–15

Böger R.H., Bode-Böger S.M. The clinical pharmacology of L-arginine// Annu Rev Pharmacol Toxicol.-2011;41:79–99.

Tanimura J. Studies on arginine in human semen. II. The effects of medication with L-arginine-HCL on male infertility// Bull Osaka Med Sch. -1967;13:84–9.

Angeli G., De-Barros T.L., De-Barros D.F., Lima M. Investigation of the effects of oral supple-mentation of arginine in the increase of muscular strength and mass// Braz J Sports Med.- 2007;13:129–32.

Fossel E.T. Improvement of temperature and flow in feet of subjects with diabetes with use of a transdermal preparation of L-arginine: A pilot study// Diabetes Care. -2004;27:284–5.

Klahr S. Can L-arginine manipulation reduce renal disease? //Semin Nephrol. -1999;19:304–9.

Collier S.R., Casey D.P., Kanaley J.A. Growth hormone responses to varying doses of oral argi-nine//Growth Horm IGF Res.- 2005;15:136–9.

Arakawa T., Kita Y., Koyama A.H. Solubility enhancement of gluten and organic compounds by arginine//Int J Pharm.- 2008;355:220–3.

Hirano A., Arakawa T., Shiraki K. Arginine increases the solubility of coumarin: Comparison with salting-in and salting-out additives// J Biochem.- 2008;144:363–9.

Tapiero H., Mathé G., Couvreur P., Tew K. I. Arginine// Biomed Pharmacother.- 2002.- Nov;56 (9):439-45.

Rainer H. Böger.The Pharmacodynamics of L-Arginine//American Society for Nutrition.- 2007.- 441 р.

Merimee T.J., Rabinovitz D., Riggs L., Burgessi J.A., Rimoin D.L., Cokusick V.A. Plasma growth hormone after arginine injection// N Engl J Med.- 1967;276:434–9.

Bode-Böger S.M., Böger R.H., Creutzig A., Tsikas D. et all.L-Arginine infusion decreases peripheral arterial resistance and inhibits platelet aggregation in healthy volunteers.// Clin Sci.- 1994;87:303–10.

Bode-Böger S.M., Böger R.H., Alfke H., Heinzel D., Tsikas D. et.all. L-arginine induces NO-dependent vaso-dilation in patients with critical limb ischemia - a randomized, controlled study// Circulation.-1996;93:85–90.

Bode-Böger S.M., Böger R.H., Galland A., Junker W., Tsikas D., Frölich J.C. Pharmacokinetic-pharmacodynamic relationship of the effects of intravenous and oral L-arginine on nitric oxide formation and peripheral haemodynamics in healthy human subjects//Br J Clin Pharmacol.- 1998;46:489–97.

Böger R.H., Bode-Böger S.M., Heinzel D., Höper M., Mügge A., Frölich J.C. Differential systemic and pul-monary haemodynamic effects of L-arginine in patients with coronary heart disease and primary pulmonary hypertension// Int J Clin Pharmacol Ther.- 1996;34:323–8.

Drexler H., Zeiher A.M., Meinzer K., Just H. Correction of endothelial dysfunction in coronary mi-crocirculation of hypercholesterolaemic patients by L-arginine// Lancet.- 1991;338:1546–50.

Ceremuzynski L., Chamiec T., Herbaczynska-Cedro K. Effect of supplemental oral L-arginine on exercise capacity in patients with stable angina pectoris// Am J Cardiol. -1997;80:331–3.

Bednarz B., Wolk R., Chamiec T., Herbaczynska-Cedro K., Winek D., Ceremuzynski L. Effects of oral L-arginine supplementation on exercise-induced QT dispersion and exercise tolerance in stable angina pectoris// Int J Cardiol.-2000;75:205–10.

Bednarz B., Jaxa-Chamiec T., Gebalska J., Herbaczynska-Cedro K., Ceremuzynski L. L-Arginine supplementation prolongs exercise capacity in congestive heart failure// Kardiol Pol. - 2004;60:348–53.

Bednarz B., Jaxa-Chamiec T., Maciejewski P., Szpajer M., Janik K. et. al. Efficacy and safety of oral l-arginine in acute myocardial infarction. Results of the multicenter, randomized, double-blind, placebo-controlled ARAMI pilot trial//Kardiol Pol.-2005;62:421–7.

Böger R.H. Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medi-cine and beyond// Ann Med. - 2006;38:126–36.

Zeynalov Е., Susan M. Jones. Recent advances and future directions in preclinical research of arginine-vasopressin (AVP) receptor blocker conivaptan in the context of stroke// Neural Regen Res.- 2016 Mar; 11(3): 392–393.

Abdullah Shafique Ahmad, Zahoor Ahmad Shah, Sylvain Doré. Protective Role of Arginase II in Cerebral Ischemia and Excitotoxicity//J Neurol Neurosci.- 2016; 7(2): 88.

Wahlestedt C., Golanov E., Yamamoto S., Yee F., Ericson H., et al. Antisense oligodeoxynucleo-tides to NMDA-R1 receptor channel protect cortical neurons from excitotoxicity and reduce focal ischaemic infarctions //Nature.- 1993;363:260–263.

Szatkowski M., Attwell D. Triggering and execution of neuronal death in brain ischaemia: two phases of glutamate release by different mechanisms // Trends Neurosci.- 1994;17:359–365.

Murphy S., Gibson C.L. Nitric oxide, ischaemia and brain inflammation //Biochem Soc Trans.-2007;35:1133–1137.

Kitaura H., Uozumi N., Tohmi M., Yamazaki M., Sakimura K., et al. Roles of nitric oxide as a vasodilator in neurovascular coupling of mouse somatosensory cortex// Neurosci Res. - 2007;59:160–171.

Pacher P., Beckman J.S., Liaudet L. Nitric oxide and peroxynitrite in health and dis-ease // Physiological Reviews. - 2007;87:315–424.

Szabo C., Ischiropoulos H., Radi R. Peroxynitrite: biochemistry, pathophysiology and develop-ment of therapeutics // Nat Rev Drug Discov.- 2007;6:662–680.

Lim H.K., Ryoo S., Benjo A., Shuleri K., Miriel V., et al. Mitochondrial arginase II constrains endothelial NOS-3 activity // Am J Physiol Heart Circ Physiol. -2007;293:H3317–H3324.

Steppan J., Nyhan D., Berkowitz D. Development of novel arginase inhibitors for therapy of endothelial dysfunction // Front Immunol.- 2013;443-449

Choi D.W. Excitotoxic cell death// J Neurobiol. -1992;23:1261–1276.

Ayata C., Ayata G., Hara H., Matthews R.T., Beal M.F., et al. Mechanisms of reduced striatal NMDA excitotoxicity in type I nitric oxide synthase knock-out mice// J Neurosci - 1997;17:6908–6917.

Iadecola C., Niwa K., Nogawa S., Zhao X., Nagayama M., et al. Reduced susceptibility to is-chemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice // Proc Natl Acad Sci USA. - 2001;98:1294–1299.

Lynch D.R., Guttmann R.P. Excitotoxicity: perspectives based on N-methyl-D-aspartate recep-tor subtypes //J Pharmacol Exp Ther. -2002;300:717–723.

Lafon-Cazal M., Pietri S., Culcasi M., Bockaert J. NMDA-dependent superoxide production and neurotoxicity. Nature. 1993;364:535–537.

Cull-Candy S., Brickley S., Farrant M. NMDA receptor subunits: diversity, development and disease.Curr Opin Neurobiol. 2001;11:327–335.

Dawson V.L., Dawson T.M., London E.D., Bredt D.S., Snyder S.H. Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures. Proc Natl Acad Sci USA. 1991;88:6368–6371.

Diego Milani, Vince W. Clark, Jane L. Cross, Ryan S. Anderton et. al. Poly-arginine peptides reduce infarct volume in a permanent middle cerebral artery rat stroke model// BMC/ Neurosci.- 2016; 17: 19.

Campbell B.C., Mitchell P.J., Kleinig T.J., Dewey H.M., Churilov L., Yassi N., et. al. Investigators Endovascular therapy for ischemic stroke with perfusion-imaging selection //N Engl J Med.- 2015;372:1009–1018.

Goyal M., Demchuk A.M., Menon B.K., Eesa M., Rempel J.L., Thornton J., Roy D., et. al. Trial Investigators Randomized assessment of rapid endovascular treatment of ischemic stroke// N Engl J Med. -2015;372:1019–1030.

Jovin T.G., Chamorro A., Cobo E., de Miquel M.A., Molina C.A., Rovira A., et. al. Trial Investigators Thrombectomy within 8 hours after symptom onset in ischemic stroke// N Engl J Med. -2015;372:2296–2306.

Donnan G.A., Fisher M., Macleod M., Davis S.M // Stroke Lancet. -2008;371:1612–1623.

Meloni B.P., Craig A.J., Milech N., Hopkins R.M., Watt P.M., Knuckey N.W. The neuroprotective efficacy of cell-penetrating peptides TAT, penetratin, Arg-9, and Pep-1 in glutamic acid, kainic acid, and in vitro ischemia injury models using primary cortical neuronal cultures //Cell Mol Neurobiol. -2014;34:173–181.

Meloni B.P., Brookes L.M., Clark V.W., Cross J.L., Edwards A.B., et. al. Poly-arginine and arginine-rich peptides are neuroprotective in stroke models// J Cereb Blood Flow Metab. - 2015;35:993–1004.

Meloni B.P., Cross J.L., Edwards A.B., Anderton R.S., O’Hare Doig R.L, et. al. Neuroprotective peptides fused to arginine-rich cell penetrating peptides: neuropro-tective mechanism likely mediated by peptide endocytic properties // Pharmacol Ther. - 2015;153:36–54.

Marshall J, Wong KY, Rupasinghe CN, Tiwari R, Zhao X, Berberoglu ED, et. al. Inhibition of N-methyl-D-aspartate-induced retinal neuronal death by polyarginine peptides is linked to the attenuation of stress-induced hyperpolar-ization of the inner mitochondrial membrane potential. J Biol Chem. 2015;290:22030–22048.

Janja Pretnar-Oblak. Cerebral Endothelial Function Determined by Cerebrovascular Reactivity to L-Arginine// Biomed Res Int.- 2014; 2014: 601515.

Strandgaard S., Paulson O.B. Regulation of cerebral blood flow in health and disease// Journal of Cardiovascular Pharmacology.- 1992;19(supplement 6):S89–S93.

Tousoulis D., Davies G.J., Tentolouris C., et al. Effects of changing the availability of the substrate for nitric oxide synthase by L-arginine administration on coronary vasomotor tone in angina patients with angiographically narrowed and in patients with normal coronary arteries //The American Journal of Cardiology. -1998;82(9):1110–1113.

Raitakari O.T., Celermajer D.S. Flow-mediated dilatation // British Journal of Clinical Pharmacology.- 2000;50(5):397–404.

Perko D., Pretnar-Oblak J., Šabovič M., Žvan B., Zaletel M. Differences between cerebrovascular reactivity to L-arginine in the anterior and posterior cerebral circulation// Cerebrovascular Diseases.- 2011;31(4):358–364.

Celermajer D.S., Sorensen K.E., Gooch V.M., et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis //The Lancet. - 1992;340(8828):1111–1115

Pretnar-Oblak J., Zaletel M., Zvan B., Sabovic M., Pogacnik T. Cerebrovascular reactivity to L-arginine in patients with lacunar infarctions // Cerebrovascular Diseases.- 2006;21(3):180–186.

Kozera G.M., Wolnik B., Kunicka K.B., et al. Cerebrovascular reactivity, intima-media thickness, and nephropathy presence in patients with type 1 diabetes// Diabetes Care. -2009;32(5):878–882.

Kozera G.M., Dubaniewicz M., Zdrojewski T., et al. Cerebral vasomotor reactivity and extent of white matter lesions in middle-aged men with arterial hypertension: a pilot study// The American Journal of Hypertension.- 2010;23(11):1198–1203.

Micieli G., Bosone D., Zappoli F., Marcheselli S., Argenteri A., Nappi G. Vasomotor response to CO2 and L-Arginine in patients with severe internal carotid artery stenosis; pre- and post-surgical evaluation with transcranial Doppler// Journal of the Neurological Sciences.- 1999;163(2):153–158.

Zvan B., Zaletel M., Pogacnik T., Kiauta T. Testing of cerebral endothelium function with L-arginine after stroke// International Angiology.- 2002;21(3):256–259

Zimmermann C., Wimmer M., Haberl R.L. L-arginine-mediated vasoreactivity in patients with a risk of stroke // Cerebrovascular Diseases.- 2004;17(2-3):128–133.

Wei H.M., Chi O.Z., Liu X., Sinha A.K., Weiss H.R. Nitric oxide synthase inhibition alters cerebral blood flow and oxygen balance in focal cerebral ischemia in rats// Stroke. -1994;25(2):445–450.

Margaill I., Allix M., Boulu R.G., Plotkine M. Dose- and time-dependence of L-NAME neuroprotection in transient focal cerebral ischaemia in rats// British Journal of Pharmacology.- 1997;120(1):160–163.

Pretnar-Oblak J., Sabovic M., Sebestjen M., Pogacnik T., Zaletel M. Influence of atorvastatin treatment on L-arginine cerebrovascular reactivity and flow-mediated dilatation in patients with lacunar infarctions// Stroke. 2006;37(10):2540–2545.

Mitchell G.F., Parise H., Vita J.A., et al. Local shear stress and brachial artery flow-mediated dilation: the Framingham heart study// Hypertension.- 2004;44(2):134–139.

Amarenco P., Lavallée P., Touboul P.//J. Statins and stroke prevention.- Cerebrovascular Diseases. -2004;17(1):81–88.